



HEIDELBERG UNIVERSITY HOSPITAL



SCIENTIFIC PROGRAM

8TH HEIDELBERG MYELOMA WORKSHOP

MULTIPLE MYELOMA – TODAY AND TOMORROW

Congress venue:

Online - Event

FRIDAY, APRIL 16TH, 2021

SATURDAY, APRIL 17TH, 2021



NCT

NATIONAL CENTER
FOR TUMOR DISEASES
HEIDELBERG



DEAR COLLEAGUES,

Welcome to the 8th Heidelberg Myeloma Workshop.

Recent years have seen myeloma patients benefit from more refined diagnostic criteria and a wider range of treatment options. In particular, immunotherapies such as CAR T-cell therapy have a high potential to improve myeloma therapy. Other immunotherapeutic treatments are based on bispecific antibodies and so-called antibody-drug conjugates. Both the earlier initiation of treatment and a greater appreciation of the importance of targeting sustained deep remissions offer new opportunities to further extend patient survival.

A precise delineation of the prognosis of different patient groups can be achieved by the detection of genetic alterations and characteristic clinical and molecular markers. Trendsetting are the methods of imaging and molecular medicine, which are combined within the framework of systems medicine and continuously improve our understanding of the disease.

The 8th Heidelberg Myeloma Workshop will start at 11.45 a.m. on Friday, the 16th of April, 2021. We hope that this program will be of interest to you and look forward to welcoming you at our virtual event.

Sincerely,



Prof. Dr. Hartmut Goldschmidt



Prof. Dr. Marc-Steffen Raab



Dr. rer. nat. Niels Weinhold

FRIDAY, APRIL 16TH, 2021

11.30 a.m. – 11.45 a.m. Online Registration

11.45 a.m. – 12.00 p.m.

Introduction and Opening Remarks – 8th Heidelberg Myeloma Workshop

Hartmut Goldschmidt, Heidelberg

Marc S. Raab, Heidelberg

Carsten Müller-Tidow, Heidelberg

Ingo Autenrieth, Heidelberg

SESSION I

12.00 p.m. – 1.45 p.m.

Diagnostics and Prognostic Factors

Chairmen: Niels Weinhold, Heidelberg

12.00 p.m. – 12.25 p.m.

Risk to progression in SMM

Maria Victoria Mateos, Salamanca

12.25 p.m. – 12.50 p.m.

How to define high-risk MM

Herve Avet-Loiseau, Toulouse

12.50 p.m. – 1.15 p.m.

Imaging based predictors of disease progression

Jens Hillengass, Buffalo

KEY NOTE LECTURE

1.15 p.m. – 1.45 p.m.

COVID-19 and other vaccinations

Heinz Ludwig, Wien

1.45 p.m. – 2.15 p.m.

Coffee Break - optional:
Virtual Networking Room

SESSION II

2.15 p.m. – 3.55 p.m.

Advances in Immunotherapie

Chairmen: Michael Schmitt, Heidelberg

2.15 p.m. – 2.40 p.m.

Antibody-drug conjugates

Sagar Lonial, Atlanta

2.40 p.m. – 3.05 p.m.

Antibody-based T-Cell engagers

Marc-Steffen Raab, Heidelberg

3.05 p.m. – 3.30 p.m.

CAR-T cells targeting BCMA

Nikhil Munshi, Boston

3.30 p.m. – 3.55 p.m.

CARs beyond BCMA

Michael Hudecek, Würzburg

3.55 p.m. – 4.10 p.m.

Virtual Short Coffee Break

SESSION III

4.10 p.m. – 6.20 p.m.

Current and future treatment standards

Chairmen: Florian Bassermann

4.10 p.m. – 4.35 p.m.

Should we treat SMM?

Ola Landgren, Miami

4.35 p.m. – 5.00 p.m.

High-risk MM

Katja Weisel, Hamburg

5.00 p.m. - 5.25 p.m.

Relapsed MM

Christoph Scheid, Köln

5.25 p.m.- 5.50 p.m.

First-line treatment in transplant-eligible patients

Phillippe Moreau, Nantes

KEY NOTE LECTURE

5.50 p.m. – 6.20 p.m.

Are we going to cure myeloma?

Brian Durie, Los Angeles

6.20 p.m.- 6.35 p.m.

Summary - Day one

Marc S. Raab / Hartmut Goldschmidt, Heidelberg

SATURDAY, APRIL 17TH, 2021

SESSION IV 8.30 a.m. – 10.40 a.m.
MRD Driven Therapy – the new normal in Myeloma
Chairmen: Leo Rasche, Würzburg

8.30 a.m. – 8.55 a.m.
How to test MRD
Stefanie Huhn, Heidelberg

8.55 a.m. – 9.20 a.m.
Imaging and MRD
Elena Zamagni, Bologna

9.20 a.m. – 9.45 a.m.
Ready for guiding therapeutic decisions
Bruno Paiva, Pamplona

9.45 a.m. – 10.10 a.m.
Challenges and hurdles
Martin Kaiser, London

KEY NOTE LECTURE 10.10 a.m. – 10.40 a.m.
Screening for monoclonal gammopathy of undetermined significance: A population-based randomized clinical trial-the iStopMM study
Sigurdur Kristinsson, Reykjavik

10.40 a.m. – 10.55 a.m. Virtual Coffee Break - optional:
Virtual Networking Room

SESSION V 10.55 a.m. - 2.00 p.m.
Biology and Genomics of Multiple Myeloma
Chairmen: Christoph Driessen, St. Gallen

10.55 a.m. – 11.20 a.m.
Genomics of early MM
Niccolo Bolli, Milano

11.20 a.m. – 11.45 a.m.
Mechanisms in drug resistance
Martin Kortüm, Würzburg

11.45 a.m. – 12.10 p.m.
Future of Cereblon as a therapeutic target
Jan Krönke, Berlin

12.10 p.m. – 12.35 p.m.
Lessons from circulating tumor cells
Jens Lohr, Boston

12.35 p.m. – 1.00 p.m.

Spatial clonal evolution

Niels Weinhold, Heidelberg

1.00 p.m. – 1.30 p.m.

Lunch Break - optional:
Virtual Networking Room

KEY NOTE LECTURE

1.30 p.m. – 2.00 p.m.

Can biology guide treatment decisions in MM?

Gareth Morgan, New York

SESSION VI

2.00 p.m. – 2.50 p.m.

German Study Groups – Quo vadis?

Chairmen: Roman Hajek, Ostrava

2.00 p.m. – 2.25 p.m.

DSMM

Hermann Einsele, Würzburg

2.25 p.m. – 2.50 p.m.

GMMG

Hartmut Goldschmidt, Heidelberg

2.50 p.m. – 3.05 p.m.

Summary of the 8th Heidelberg Myeloma Workshop

Marc S. Raab / Hartmut Goldschmidt

ORGANISATION AND CONGRESS VENUE

8TH HEIDELBERG MYELOMA WORKSHOP -

University Hospital Heidelberg
Department of Medicine V and
National Center for Tumor Diseases (NCT)
Multiple Myeloma Section
Im Neuenheimer Feld 410 | 69120 Heidelberg

CONTACT AND REGISTRATION

Nina Recke
Sektion Multiples Myelom
Medizinische Klinik V
Universitätsklinikum Heidelberg

Phone: + 49 6221 56-8009
E-Mail: nina.recke@med.uni-heidelberg.de
Register online at: www.myelomaworkshop.de

We would like to thank all our sponsors for supporting the 8th Heidelberg Myeloma Workshop:



AbbVie Deutschland GmbH & Co. KG
65189 Wiesbaden | 12.500 €



Adaptive Biotechnologies
Seattle, Washington 98102 | 12.500 €



Amgen GmbH
80992 München | 20.000 €



Bristol-Myers Squibb GmbH & Co. KGaA/Celgene
80636 München | 20.000 €



GlaxoSmithKline GmbH & Co. KG
81675 München | 12.500 €



Janssen-Cilag GmbH
41470 Neuss | 20.000 €



Oncopeptides AB
11153 Stockholm | 5.000 €



Pfizer Pharma GmbH
10785 Berlin | 5.000 €



Roche Pharma AG
79639 Grenzach-Wyhlen | 2.000 €



Sanofi-Aventis Deutschland GmbH
10785 Berlin | 20.000 €



Sebia Labordiagnostische Systeme GmbH
36041 Fulda | 2.000 €



Siemens Healthcare GmbH
65760 Eschborn | 1.000 €



Takeda Pharma Vertrieb GmbH & Co. KG
10117 Berlin | 6.500 €



The Binding Site GmbH
68723 Schwetzingen | 2.000 €

Sponsors will receive the opportunity to advertise their products online before and/or after the event.